Allos to continue Phase II PDX trial

For the third time, an independent DMC recommended continuation of ALTH's pivotal Phase II PROPEL trial of pralatrexate ( PDX) to treat relapsed or refractory peripheral T cell lymphoma (PTCL) in abou...